Copyright
©The Author(s) 2019.
World J Gastroenterol. May 28, 2019; 25(20): 2473-2488
Published online May 28, 2019. doi: 10.3748/wjg.v25.i20.2473
Published online May 28, 2019. doi: 10.3748/wjg.v25.i20.2473
Table 1 Baseline characteristics of the study population
HCs (n = 500) | ITB (n = 133) | CD (n = 128) | P-value | |
Gender (Female/male) | 237/263 | 37/96 | 42/86 | 0.42 |
Age of diagnosis (yr) | 38.5 ± 12.8 | 41.0 ± 17.2 | 37.4 ± 16.1 | 0.06 |
Smokers, n (%) | 103/500 (20.6) | 32/133 (24.1) | 22/128 (17.2) | 0.22 |
Drinkers, n (%) | 56/500 (11.2) | 17/133 (12.8) | 15/128 (11.7) | 0.85 |
WBC (109/L) | 7.08 ± 4.0 | 7.95 ± 3.5 | 0.10 | |
Hb, g/L | 113.56 ± 23.1 | 109.83 ± 25.8 | 0.28 | |
ESR, mm/h | 37.43 ± 25.6 | 34.60 ± 25.6 | 0.50 | |
PPD (positive), n (%) | 34/49 (69.4) | 11/35 (31.4) | 0.06 | |
T-SPOT (positive), n (%) | 20/26 (76.9) | 3/27 (11.1) | 0.002 | |
TB not examined | 58 | 62 | ||
Abnormal lung imaging findings, n (%) | 50/133 (37.6) | 3/128 (2.3) | < 0.0001 | |
Remission rate: n (%) | ||||
5-ASA | 77/128 (60.2) | |||
Glucocorticoids | 31/128 (24.2) | |||
Immunosuppressors | 5/128 (3.9) | |||
Anti-TNF | 8/128 (6.2) | |||
Non-remission | 7/128 (5.5) | |||
Disease related surgery, n (%) | 21/133 (15.8) | 29/128 (22.7) | 0.21 | |
Location of ITB, n (%) | ||||
Small intestine | 11/133 (8.3) | |||
Ileocecus | 77/133 (57.9) | |||
Colon | 37/133 (27.8) | |||
Data not available | 8/133 (6.0) | |||
Location of CD, n (%) | ||||
L1 ± L4 | 60/128 (46.9) | |||
L2 ± L4 | 36/128 (28.1) | |||
L3 ± L4 | 29/128 (22.7) | |||
L4 | 3/128 (2.3) | |||
Behavior of CD, n (%) | ||||
B1—Inflammatory | 81/128 (63.3) | |||
B2—Stricturing | 37/128 (28.9) | |||
B3—Penetrating | 10/128 (7.8) | |||
p—Perianal | 35/128 (27.3) |
Table 2 Genotype and allele frequency distributions of rs2227473 in the intestinal tuberculosis and healthy control groups
Table 3 Genotype and allele frequency distributions of rs2227473 in the Crohn's disease and healthy control groups
Table 4 Genotype and allele frequency distributions of rs2227473 in the intestinal tuberculosis and Crohn's disease groups
Table 5 Genotype and allele frequency distributions of rs1143627 in the intestinal tuberculosis and healthy control groups
Table 6 Genotype and allele frequency distributions of rs1143627 in the Crohn’s disease and healthy controls groups
Table 7 Genotype and allele frequency distributions of rs1143627 in the intestinal tuberculosis and Crohn's disease groups
Table 8 Genetic model analysis of rs2227473 in the intestinal tuberculosis population
Genetic model | Genotype | HCs (n) | ITB (n) | OR (95%CI) | P-value | OR (95%CI)1 | P-value1 |
Dominant | GG | 373 | 112 | 1.00 | 1.00 | ||
GA + AA | 127 | 21 | 0.58 (0.35-0.96) | 0.034 | 0.58 (0.34-0.98) | 0.040 | |
Recessive | GA + GG | 483 | 131 | 1.00 | 1.00 | ||
AA | 17 | 2 | 0.43 (0.10-1.90) | 0.268 | 0.45 (0.10-1.99) | 0.291 | |
Co-dominant | GG | 373 | 112 | 1.00 | 1.00 | ||
AA | 17 | 2 | 0.40 (0.09-1.74) | 0.219 | 0.50 (0.11-2.33) | 0.379 | |
GG | 373 | 112 | 1.00 | 1.00 | |||
GA | 110 | 19 | 0.61 (0.36-1.03) | 0.064 | 0.63 (0.37-1.08) | 0.091 |
Table 9 Genetic model analysis of rs1143627 in the intestinal tuberculosis population
Genetic model | Genotype | HCs (n) | ITB (n) | OR (95%CI) | P-value | OR (95%CI)1 | P-value1 |
Dominant | CC | 137 | 22 | 1.00 | 1.00 | ||
CT + TT | 363 | 111 | 1.90 (1.16-3.13) | 0.011 | 1.93 (1.14-3.25) | 0.014 | |
Recessive | CT + CC | 377 | 91 | 1.00 | 1.00 | ||
TT | 123 | 42 | 1.42 (0.93-2.15) | 0.104 | 1.41 (0.92-2.18) | 0.118 | |
Co-dominant | CC | 137 | 22 | 1.00 | 1.00 | ||
TT | 123 | 42 | 2.13 (1.20-3.76) | 0.010 | 3.46 (1.73-6.91) | 0.000 | |
CC | 137 | 22 | 1.00 | 1.00 | |||
CT | 240 | 69 | 1.79 (1.06-3.02) | 0.029 | 2.14 (1.22-3.77) | 0.008 |
- Citation: Yu ZQ, Wang WF, Dai YC, Chen XC, Chen JY. Interleukin-22 receptor 1 is expressed in multinucleated giant cells: A study on intestinal tuberculosis and Crohn's disease. World J Gastroenterol 2019; 25(20): 2473-2488
- URL: https://www.wjgnet.com/1007-9327/full/v25/i20/2473.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i20.2473